Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-04-17
2007-04-17
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S501000, C436S518000
Reexamination Certificate
active
11152765
ABSTRACT:
The present invention relates to the diagnosis of colorectal cancer. It discloses the use of the protein nicotinamide N-methyltransferase (NNMT) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring NNMT in said sample. Measurement of NNMT can, e.g., be used in the early detection or diagnosis of colorectal cancer.
REFERENCES:
patent: 5733748 (1998-03-01), Yu et al.
patent: 5830677 (1998-11-01), Wu et al.
patent: 5939265 (1999-08-01), Cohen et al.
patent: WO 95/16919 (1995-06-01), None
patent: WO 00/12702 (2000-03-01), None
patent: WO 01/36977 (2001-05-01), None
patent: WO 01/73027 (2001-10-01), None
patent: WO 01/96388 (2001-12-01), None
patent: WO 01/96389 (2001-12-01), None
patent: WO 01/96390 (2001-12-01), None
patent: WO 02/12280 (2002-02-01), None
patent: WO 02/12328 (2002-02-01), None
patent: WO 02/20986 (2002-04-01), None
patent: WO 02/078636 (2002-10-01), None
patent: WO 02/090512 (2002-11-01), None
patent: WO 2004/057336 (2004-07-01), None
Aoyama et al, Neurocience Letters 298:78-80, Jan. 26, 2001.
Rozen, Postgrad Med J 77:289-291, May 2001.
Williams et al, Sem Surg Oncol 8:89-93, 1992.
Contasta et al, Cancer Biother Radiopham 18:549-557, 2003.
Ahlquist, D.A. et al., “Fecal Occult Blood Testing for Colorectal Cancer,” CGastroenterology Clinics of North America; Colorectal Neoplasia, Part II: Diagnosis & Treatment, vol. 26, No. 1, Mar. 1997, pp. 41-55.
Aksoy, S. et al., “Human Liver Nicotinadime N-Methyltransferase,” The Journal of Biological Chemistry, col. 269, No. 20, May 20, 1994, 14835-14840.
Anderson, W.F. et al., “Colorectal Cancer Screening for Persons at Average Risk,” Journal of the National Cancer Institute, vol. 94, No. 15, Aug. 7, 2002, pp. 1126-1133.
Aoyama, K. et al, “Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease,” Neuroscience Letters 298 (2001) 78-80.
Birkenkamp-Demtroder, K. et al., “Gene Expression in Colorectal Cancer,” Cancer Research 62, 4352-4363, Aug. 1, 2002.
Bruck, Cl. Et a., “Purification of Mouse Monoclonal Antibodies from Ascitic Fluid by DEAE affi-Gel Blue Chromatography,” Methods in Enzymology, vol. 121 (1986) 587-596.
Brünagel, G. et al., “Identification of Nuclear Matrix Protein Alterations Associated with Human Colon Cancer,” Cancer Research 62, 2437-2442, Apr. 15, 2002.
Carpelan-Holmström M. et al., “CEA, CA 19-9 and CA 72-4 Improve the Diagnostic Accurary in Gastrointestinal Cancers,” Anticancer Research 22;2311-2316 (2002).
Carriquiry, L. Al. et al., “Should Carcinoembryonic Antigen be Used in the Management of Patients with Colorectal Cancer?” Dis Colon Rectum, Jul. 1999, pp. 921-929.
De Marzo, A. M. et al., “Abnormal Regulation of DNA Methyltransferase Expression during Colorecal Carcinogenis,” Cancer Research 59, 3855-3860, Aug. 15, 1999.
Galfrè, G. et al., “Preparation of Monoclonal Antibodies: Strategies and Procedures,” Methods in Enzymology, vol. 73 (1981) 3-46.
Geenan, J. et al., “Major Complications of Coloscopy: Bleeding and Perforation,” Digestive Diseases, vol. 20, No. 3, (Mar. 1975) 231-235.
Goldenberg D. M. et al., “Carcinoembryonic Antigen in Histopathology: Immunoperoxidase Staining of Conventional Tissue Sections,” J. Natl Cancer Inst., vol. 57, No. 1, Jul. 1976, pp. 11-22.
Halm, U. et al., “Improved Sensitivity of Fuzzing Logic Based Tumor Marker Profiles for Diagnosis of Pancreatic Carcinoma Versus Benign Pancreatic Disease,” Anticancer research 20: 4957-4960 (2000).
Herrera, M. A. et al., “Carcinoembryonic Antigen (CEA) as a Prognostic and Monitoring Test in Clinically Complete Resection of Colorectal Carcinoma,” Ann. Surg, Jan. 1976, pp. 5-9.
Kassem, H. et al., “A Potential Role of Heat Shcok Proteins and Nicotinamide N-Methyl Transferase in Predicting Response to Radiation in Bladder Cancer,” Int. J. Cancer: 101, 454-460 (2002).
Keller, T. et al., “Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles,” J. Cancer Res Clin Oncol (1998) 124: 565-574.
Martell, R.E. et al., “OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders,” The International Journal of Biological Markers, vol. 13, No. 3, pp. 145-149 (1998).
Moertel, C.G. et al., “An Evaluation of the Carcinoembryonic Antigen (CEA) Test fro Monitoring Patients with Resected Colon Cancer,” JAMA, Aug. 25, 1993, vol. 270, No. 8, pp. 943947.
Okamura, A. et al., “Increased Hepatic Nicotinamide N-Methyltransferase Activity as a Marker of Cancer Cachexia in Mice Bearing Colon 26 Adenocarcinoma,” Jpn. J. Cancer Res. 89, 649-656, Jun. 1998.
Reynoso, G. et al., “Carcinoembryonic Antigen in Patients with Different Cancers,” JAMA, Apr. 17, 1972, vol. 220, No. 3, 361-365.
Silvis, S. E. et al., “Endoscopic Complications; Results of the 1974 American Society for Gastrointestinal Endoscopy Survey,” JAMA, Mar. 1, 1976, vol. 235, No. 9, 928-930.
Srinivas, P.R. et al., “Proteomics for Cancer Biomarker Discovery,” Clinical Chemistry 48:8, 1160-1169 (2002).
Studier, F.W. et al., “Use of T7 RNA Polymerase to Direct Expression of Cloned Genes,” Methods in Enzymology, vol. 185, (1990) 60-89.
Sturgeon, C., “Practice Guidelines for Tumor Marker Use in the Clinic,” Clinical Chemistry 48:8 1151-1159 (2002).
Wanebo, H. J. et al., “Preoperative Carcinoembryonic Antigen Level as a Prognostic Indicator I Colorectal Cancer,” The New England Journal of Medicine, vol. 299, No. 9, Aug. 31, 1978, 448-451.
Zweig, M. H. et al., “Receiver Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicaine,” Clinical Chemistry (1993) 561-577.
UICC International Union Against Cancer, Sobin, L.H. et al. Ch (eds.) TNM, Classification of Malignant Tumours, fifth edition, 1997.
Diamandis, E., Immunoassay, Academic Press, Boston, 1996.
Tijssen, P. Preparation of enzyme-antibody or other enzyme-macromolecule conjugates, Practice and Theory of Enzyme Immunoassays, (1990) 221-278.
Berndt Peter
Hagmann Marie-Luise
Karl Johann
Kott Theresa
Langen Hanno
Amick Marilyn L.
Halvorson Mark
Roche Diagnostics Operations Inc.
Roche Diagnostics Operations Inc.
Yu Misook
LandOfFree
Nicotinamide N-methyltransferase as a marker for colorectal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotinamide N-methyltransferase as a marker for colorectal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotinamide N-methyltransferase as a marker for colorectal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3756771